Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference

Erlotinib: Recent Clinical Results and Ongoing Studies in Non–Small Cell Lung Cancer
Roman Perez-Soler .................................................................................................................. 4589s

HKI-272 in Non–Small Cell Lung Cancer
Kwok-Kin Wong ...................................................................................................................... 4593s

Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab
Mark A. Socinski ..................................................................................................................... 4597s

Is There a Role for Cetuximab in Non–Small Cell Lung Cancer?
Daniel Morgensztern and Ramaswamy Govindan .................................................................... 4602s

Selecting Patients for Treatment with Epidermal Growth Factor Tyrosine Kinase Inhibitors
Philip D. Bonomi, Lela Buckingham, and John Coon ................................................................ 4606s

Bevacizumab in Non–Small Cell Lung Cancer
Alan Sandler ............................................................................................................................. 4613s

Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer
Emer O. Hanrahan and John V. Heymach ................................................................................ 4617s

Vascular Endothelial Growth Factor Trap in Non–Small Cell Lung Cancer
Gregory J. Riely and Vincent A. Miller ..................................................................................... 4623s

Rationale for a Phase I Trial of Erlotinib and the Mammalian Target of Rapamycin Inhibitor Everolimus (RAD001) for Patients with Relapsed Non–Small Cell Lung Cancer
Bruce E. Johnson, David Jackman, and Pasi A. Jänne .............................................................. 4628s

Antagonism of Platelet-Derived Growth Factor Receptor in Non–Small Cell Lung Cancer: Rationale and Investigations
Julie E. Bauman, Keith D. Eaton, and Renato G. Martins ......................................................... 4632s

The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer
Jeffrey A. Engelman ................................................................................................................ 4637s

Enzastaurin, a Protein Kinase Cβ-Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer
Roy S. Herbst, Yun Oh, Asavari Wagle, and Michael Lahn ................................................... 4641s

Incorporating Bortezomib into the Treatment of Lung Cancer
Angela M. Davies, Primo N. Lara, Jr., Philip C. Mack, and David R. Gandara ......................... 4647s

L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer
Randeep Sangha and Charles Butts ....................................................................................... 4652s
Clinical Cancer Research

13 (15)

*Clin Cancer Res* 2007;13:4589s-4582.

<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://clincancerres.aacrjournals.org/content/13/15">http://clincancerres.aacrjournals.org/content/13/15</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>